

Immunoprecipitation Market by Product (Kit, Reagent (Antibodies, Magnetic Buffer)), Type (Individual IP, Coimmunoprecipitation, CHIP), End User (Academics, Research Institutes, Pharmaceutical and Biotechnology Companies) - Global Forecast to 2024

<https://marketpublishers.com/r/I2B98692BC3EN.html>

Date: February 2019

Pages: 113

Price: US\$ 5,650.00 (Single User License)

ID: I2B98692BC3EN

Abstracts

“Increasing research activity in the life sciences industry is expected to drive the overall growth of the immunoprecipitation market.”

The immunoprecipitation market is projected to reach USD 750 million by 2024 from USD 560 million in 2018, at CAGR of 5.0% during forecast period. The growth of this market is majorly driven by the increasing number of research activities in the life sciences industry and the growing need to identify antigens associated with autoimmune diseases (through antigen-antibody interaction to understand disease mechanisms and develop relevant drugs targeting these diseases). However, the presence of alternative technologies for protein purification is expected to restrain the growth of this market in the coming years.

“The kits segment is expected to grow at the highest CAGR during the forecast period.”

The immunoprecipitation market, by product, has been categorized into three major segments— kits, reagents, and accessories. The kits segment is estimated to grow at the highest CAGR from 2018 to 2024. The need for repeat purchase of kits, coupled with the increasing number of IP assays to isolate and purify antigens, forms a major driver for the growth of this segment.

“The pharmaceutical & biotechnology companies segment is expected to grow at the highest CAGR during the forecast period.”

The immunoprecipitation market, by end user, has been categorized into three major segments—academic & research institutes, pharmaceutical & biotechnology companies, and contract research organizations (CROs). The pharmaceutical & biotechnology companies segment is estimated to grow at the highest CAGR from 2018 to 2024. The increasing demand for protein-based drugs to drive the demand for immunoprecipitation in this end-user segment will support market growth.

“Asia Pacific projected to grow at the highest CAGR during the forecast period.”

In the immunoprecipitation market, Asia Pacific is projected to record the highest growth during the forecast period. China, Japan, and India are the major markets for immunoprecipitation in the Asia Pacific. Increasing investments by governments and industries, growing biotechnology research in these regions, and rising awareness about personalized therapeutics are expected to drive the growth of these markets during the forecast period.

In-depth interviews were conducted with Chief Executive Officers (CEOs), marketing directors, other innovation and technology directors, and executives from various key organizations operating in the immunoprecipitation market.

By Company Type: Tier 1–48%, Tier 2–34%, and Tier 3–18%

By Designation: C-level Executives–42%, Directors–40%, and Others–18%

By Region: North America–38%, Europe–25%, APAC–30%, and RoW–7%

The immunoprecipitation market comprises major providers such as Thermo Fisher Scientific (US), Abcam (UK), Merck KGaA (Germany). The study includes an in-depth competitive analysis of these key players in the immunoprecipitation market, along with their company profiles, recent developments, and key market strategies.

RESEARCH COVERAGE:

The market study covers the immunoprecipitation market across various segments. It aims at estimating the market size and the growth potential of this market across different segments, on the basis of product, analyte type, product, end user, and region. The study also includes an in-depth competitive analysis of the key players in the

market, along with their company profiles, key observations related to their product and business offerings, recent developments, and key market strategies.

KEY BENEFITS OF BUYING THE REPORT:

The report will help market leaders/new entrants in this market and provide information on the closest approximations of the revenue numbers for the overall immunoprecipitation market and its subsegments. This report will help the stakeholders to understand the competitive landscape, to gain more insights to better position their businesses, and to plan suitable go-to-market strategies. The report will also help the stakeholders to understand the pulse of the market and provide information on key market drivers, restraints, and opportunities.

Contents

1 INTRODUCTION

- 1.1 OBJECTIVES OF THE STUDY
- 1.2 MARKET DEFINITION
- 1.3 MARKET SCOPE
 - 1.3.1 MARKETS COVERED
 - 1.3.2 YEARS CONSIDERED FOR THE STUDY
- 1.4 CURRENCY
- 1.5 STAKEHOLDERS
- 1.6 LIMITATIONS

2 RESEARCH METHODOLOGY

- 2.1 RESEARCH APPROACH
 - 2.1.1 SECONDARY RESEARCH
 - 2.1.1.1 Key data from secondary sources
 - 2.1.2 PRIMARY RESEARCH
 - 2.1.2.1 Key data from primary sources
 - 2.1.2.2 Break down of primaries
 - 2.1.2.3 Key industry insights
- 2.2 MARKET SIZE ESTIMATION
- 2.3 DATA TRIANGULATION APPROACH
- 2.4 ASSUMPTIONS FOR THE STUDY

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

- 4.1 IMMUNOPRECIPITATION: MARKET OVERVIEW
- 4.2 IMMUNOPRECIPITATION MARKET, BY PRODUCT (2018–2024)
- 4.3 NORTH AMERICA: IMMUNOPRECIPITATION MARKET, BY TYPE (2018)

5 MARKET OVERVIEW

- 5.1 INTRODUCTION
- 5.2 MARKET DYNAMICS
 - 5.2.1 MARKET DRIVERS

5.2.1.1 Increasing number of life sciences research activities

5.2.1.2 Growing need to identify antigens that are associated with autoimmune diseases

5.2.2 RESTRAINTS

5.2.2.1 Presence of alternative technologies

5.2.3 OPPORTUNITIES

5.2.3.1 Increasing focus on biomarker discovery

5.2.4 CHALLENGES

5.2.4.1 Quality concerns over research antibodies

6 IMMUNOPRECIPITATION MARKET, BY TYPE

6.1 INTRODUCTION

6.2 INDIVIDUAL IMMUNOPRECIPITATION

6.2.1 INCREASING DEMAND FOR BIOLOGICS IS DRIVING THE GROWTH OF THE MARKET

6.3 CO-IMMUNOPRECIPITATION

6.3.1 INCREASING USE OF CO-IP TO STUDY PROTEIN COMPLEXES FORMS A KEY MARKET DRIVER

6.4 CHROMATIN IMMUNOPRECIPITATION

6.4.1 GROWING ADOPTION OF HIGH-THROUGHPUT TECHNOLOGIES WILL CONTRIBUTE TO ADOPTION OF CHIP

6.5 RNA IMMUNOPRECIPITATION

6.5.1 AVAILABILITY OF GOVERNMENT FUNDING WILL DRIVE THE ADOPTION OF RIP KITS

7 IMMUNOPRECIPITATION MARKET, BY PRODUCT

7.1 INTRODUCTION

7.2 KITS

7.2.1 KITS SEGMENT TO ACCOUNT FOR THE LARGEST SHARE OF THE IMMUNOPRECIPITATION MARKET DURING THE FORECAST PERIOD

7.3 REAGENTS

7.3.1 ANTIBODIES

7.3.1.1 Antibodies, by type

7.3.1.1.1 Primary Antibodies

7.3.1.1.1.1 Primary antibodies to account for the largest share of the immunoprecipitation antibodies market during the forecast period

7.3.1.1.2 Secondary Antibodies

7.3.1.1.2.1 Low cost of production - A major factor driving the growth of the secondary antibodies market

7.3.2 BEADS

7.3.2.1 Beads, by type

7.3.2.2 Agarose beads

7.3.2.2.1 High binding capacity and lower cost – Factors supporting the wide use of agarose beads in research laboratories

7.3.2.3 Magnetic beads

7.3.2.3.1 Magnetic bead-based separation helps increase throughput and reduces hands-on time

7.3.2.4 Buffers

7.3.2.4.1 Buffer solutions play an important role in maintaining pH balance in IP assays

7.4 ACCESSORIES

8 IMMUNOPRECIPITATION MARKET, BY END USER

8.1 INTRODUCTION

8.2 ACADEMIC & RESEARCH INSTITUTES

8.2.1 ACADEMIC & RESEARCH INSTITUTES ARE THE LARGEST END USERS OF IMMUNOPRECIPITATION

8.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES

8.3.1 INCREASING DEMAND FOR PROTEIN-BASED DRUGS TO DRIVE THE DEMAND FOR IMMUNOPRECIPITATION IN THIS END-USER SEGMENT

8.4 CONTRACT RESEARCH ORGANIZATIONS

8.4.1 GROWTH IN OUTSOURCING OF PROTEIN PURIFICATION ACTIVITIES - A MAJOR FACTOR DRIVING THE DEMAND FOR IMMUNOPRECIPITATION TECHNOLOGIES IN CONTRACT RESEARCH ORGANIZATIONS

9 IMMUNOPRECIPITATION MARKET, BY REGION

9.1 INTRODUCTION

9.2 NORTH AMERICA

9.2.1 US

9.2.1.1 Growing research will drive market growth

9.2.2 CANADA

9.2.2.1 Increasing genomics and proteomics research to drive the adoption of immunoprecipitation in the coming years

9.3 EUROPE

9.3.1 GROWTH OF THE LIFE SCIENCES SECTOR WILL SUPPORT THE DEMAND FOR IMMUNOPRECIPITATION

9.4 ASIA PACIFIC

9.4.1 INCREASING DEMAND FOR NOVEL ANTIBODY AND PROTEIN-BASED DRUGS SUPPORT MARKET GROWTH IN THE ASIA PACIFIC

9.5 REST OF THE WORLD

10 COMPETITIVE LANDSCAPE

10.1 OVERVIEW

10.2 VENDOR BENCHMARKING

10.3 COMPETITIVE LEADERSHIP MAPPING

10.3.1 VISIONARY LEADERS

10.3.2 INNOVATORS

10.3.3 DYNAMIC DIFFERENTIATORS

10.3.4 EMERGING COMPANIES

10.4 MARKET RANKING ANALYSIS, 2017

10.5 COMPETITIVE SITUATION AND TRENDS

10.5.1 EXPANSIONS

10.5.2 COLLABORATIONS, PARTNERSHIPS, AND AGREEMENTS

10.5.3 PRODUCT LAUNCHES

10.5.4 ACQUISITIONS

11 COMPANY PROFILES

(Business overview, Products offered, Recent Developments, MNM view)*

11.1 THERMO FISHER SCIENTIFIC

11.2 ABCAM

11.3 GENSCRIPT

11.4 MERCK KGAA

11.5 BIO-RAD LABORATORIES

11.6 BIOLEGEND

11.7 TAKARA BIO

11.8 ROCKLAND IMMUNOCHEMICALS

11.9 CELL SIGNALING TECHNOLOGY

11.10 GENO TECHNOLOGY

*Details on Business overview, Products offered, Recent Developments, MNM view

might not be captured in case of unlisted companies.

12 APPENDIX

12.1 DISCUSSION GUIDE

12.2 KNOWLEDGE STORE: MARKETSandMARKETS' SUBSCRIPTION PORTAL

12.3 AVAILABLE CUSTOMIZATIONS

12.4 RELATED REPORTS

12.5 AUTHOR DETAILS

List Of Tables

LIST OF TABLES

TABLE 1 IMMUNOPRECIPITATION MARKET, BY TYPE, 2016–2024 (USD MILLION)

TABLE 2 INDIVIDUAL IMMUNOPRECIPITATION MARKET, BY REGION, 2016–2024 (USD MILLION)

TABLE 3 NORTH AMERICA: INDIVIDUAL IMMUNOPRECIPITATION MARKET, BY COUNTRY, 2016–2024 (USD MILLION)

TABLE 4 CO-IMMUNOPRECIPITATION MARKET, BY REGION, 2016–2024 (USD MILLION)

TABLE 5 NORTH AMERICA: CO-IMMUNOPRECIPITATION MARKET, BY COUNTRY, 2016–2024 (USD MILLION)

TABLE 6 CHROMATIN IMMUNOPRECIPITATION MARKET, BY REGION, 2016–2024 (USD MILLION)

TABLE 7 NORTH AMERICA: CHROMATIN IMMUNOPRECIPITATION MARKET, BY COUNTRY, 2016–2024 (USD MILLION)

TABLE 8 RNA IMMUNOPRECIPITATION MARKET, BY REGION, 2016–2024 (USD MILLION)

TABLE 9 NORTH AMERICA: RNA IMMUNOPRECIPITATION MARKET, BY COUNTRY, 2016–2024 (USD MILLION)

TABLE 10 IMMUNOPRECIPITATION MARKET, BY PRODUCT, 2016–2024 (USD MILLION)

TABLE 11 IMMUNOPRECIPITATION KITS MARKET, BY REGION, 2016–2024 (USD MILLION)

TABLE 12 NORTH AMERICA: IMMUNOPRECIPITATION KITS MARKET, BY COUNTRY, 2016–2024 (USD MILLION)

TABLE 13 IMMUNOPRECIPITATION REAGENTS MARKET, BY REGION, 2016–2024 (USD MILLION)

TABLE 14 NORTH AMERICA: IMMUNOPRECIPITATION REAGENTS MARKET, BY COUNTRY, 2016–2024 (USD MILLION)

TABLE 15 IMMUNOPRECIPITATION REAGENTS MARKET, BY TYPE, 2016–2024 (USD MILLION)

TABLE 16 IMMUNOPRECIPITATION ANTIBODIES MARKET, BY REGION, 2016–2024 (USD MILLION)

TABLE 17 NORTH AMERICA: IMMUNOPRECIPITATION ANTIBODIES MARKET, BY COUNTRY, 2016–2024 (USD MILLION)

TABLE 18 IMMUNOPRECIPITATION ANTIBODIES MARKET, BY TYPE, 2016–2024 (USD MILLION)

TABLE 19 IMMUNOPRECIPITATION MARKET FOR PRIMARY ANTIBODIES, BY REGION, 2016–2024 (USD MILLION)

TABLE 20 NORTH AMERICA: IMMUNOPRECIPITATION MARKET FOR PRIMARY ANTIBODIES, BY COUNTRY, 2016–2024 (USD MILLION)

TABLE 21 IMMUNOPRECIPITATION MARKET FOR SECONDARY ANTIBODIES, BY REGION, 2016–2024 (USD MILLION)

TABLE 22 NORTH AMERICA: IMMUNOPRECIPITATION MARKET FOR SECONDARY ANTIBODIES, BY COUNTRY, 2016–2024 (USD MILLION)

TABLE 23 IMMUNOPRECIPITATION BEADS MARKET, BY REGION, 2016–2024 (USD MILLION)

TABLE 24 NORTH AMERICA: IMMUNOPRECIPITATION BEADS MARKET, BY COUNTRY, 2016–2024 (USD MILLION)

TABLE 25 IMMUNOPRECIPITATION BEADS MARKET, BY TYPE, 2016–2024 (USD MILLION)

TABLE 26 IMMUNOPRECIPITATION MARKET FOR AGAROSE BEADS, BY REGION, 2016–2024 (USD MILLION)

TABLE 27 NORTH AMERICA: IMMUNOPRECIPITATION MARKET FOR AGAROSE BEADS, BY COUNTRY, 2016–2024 (USD MILLION)

TABLE 28 IMMUNOPRECIPITATION MARKET FOR MAGNETIC BEADS, BY REGION, 2016–2024 (USD MILLION)

TABLE 29 NORTH AMERICA: IMMUNOPRECIPITATION MARKET FOR MAGNETIC BEADS, BY COUNTRY, 2016–2024 (USD MILLION)

TABLE 30 IMMUNOPRECIPITATION BUFFERS MARKET, BY REGION, 2016–2024 (USD MILLION)

TABLE 31 NORTH AMERICA: IMMUNOPRECIPITATION BUFFERS MARKET, BY COUNTRY, 2016–2024 (USD MILLION)

TABLE 32 IMMUNOPRECIPITATION ACCESSORIES MARKET, BY REGION, 2016–2024 (USD MILLION)

TABLE 33 NORTH AMERICA: IMMUNOPRECIPITATION ACCESSORIES MARKET, BY COUNTRY, 2016–2024 (USD MILLION)

TABLE 34 IMMUNOPRECIPITATION MARKET, BY END USER, 2016–2024 (USD MILLION)

TABLE 35 IMMUNOPRECIPITATION MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2016–2024 (USD MILLION)

TABLE 36 NORTH AMERICA: IMMUNOPRECIPITATION MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2016–2024 (USD MILLION)

TABLE 37 IMMUNOPRECIPITATION MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2016–2024 (USD MILLION)

TABLE 38 NORTH AMERICA: IMMUNOPRECIPITATION MARKET FOR

PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2016–2024
(USD MILLION)

TABLE 39 IMMUNOPRECIPITATION MARKET FOR CONTRACT RESEARCH
ORGANIZATIONS, BY REGION, 2016–2024 (USD MILLION)

TABLE 40 NORTH AMERICA: IMMUNOPRECIPITATION MARKET FOR CONTRACT
RESEARCH ORGANIZATIONS, BY COUNTRY, 2016–2024 (USD MILLION)

TABLE 41 IMMUNOPRECIPITATION MARKET, BY REGION, 2016–2024 (USD
MILLION)

TABLE 42 NORTH AMERICA: IMMUNOPRECIPITATION MARKET, BY COUNTRY,
2016–2024 (USD MILLION)

TABLE 43 NORTH AMERICA: IMMUNOPRECIPITATION MARKET, BY PRODUCT,
2016–2024 (USD MILLION)

TABLE 44 NORTH AMERICA: IMMUNOPRECIPITATION REAGENTS MARKET, BY
TYPE, 2016–2024 (USD MILLION)

TABLE 45 NORTH AMERICA: IMMUNOPRECIPITATION ANTIBODIES MARKET, BY
TYPE, 2016–2024 (USD MILLION)

TABLE 46 NORTH AMERICA: IMMUNOPRECIPITATION BEADS MARKET, BY TYPE,
2016–2024 (USD MILLION)

TABLE 47 NORTH AMERICA: IMMUNOPRECIPITATION MARKET, BY TYPE,
2016–2024 (USD MILLION)

TABLE 48 NORTH AMERICA: IMMUNOPRECIPITATION MARKET, BY END USER,
2016–2024 (USD MILLION)

TABLE 49 US: IMMUNOPRECIPITATION MARKET, BY PRODUCT, 2016–2024 (USD
MILLION)

TABLE 50 US: IMMUNOPRECIPITATION REAGENTS MARKET, BY TYPE,
2016–2024 (USD MILLION)

TABLE 51 US: IMMUNOPRECIPITATION ANTIBODIES MARKET, BY TYPE,
2016–2024 (USD MILLION)

TABLE 52 US: IMMUNOPRECIPITATION BEADS MARKET, BY TYPE, 2016–2024
(USD MILLION)

TABLE 53 US: IMMUNOPRECIPITATION MARKET, BY TYPE, 2016–2024 (USD
MILLION)

TABLE 54 US: IMMUNOPRECIPITATION MARKET, BY END USER, 2016–2024 (USD
MILLION)

TABLE 55 CANADA: IMMUNOPRECIPITATION MARKET, BY PRODUCT, 2016–2024
(USD MILLION)

TABLE 56 CANADA: IMMUNOPRECIPITATION REAGENTS MARKET, BY TYPE,
2016–2024 (USD MILLION)

TABLE 57 CANADA: IMMUNOPRECIPITATION ANTIBODIES MARKET, BY TYPE,

2016–2024 (USD MILLION)

TABLE 58 CANADA: IMMUNOPRECIPITATION BEADS MARKET, BY TYPE,
2016–2024 (USD MILLION)

TABLE 59 CANADA: IMMUNOPRECIPITATION MARKET, BY TYPE, 2016–2024 (USD
MILLION)

TABLE 60 CANADA: IMMUNOPRECIPITATION MARKET, BY END USER, 2016–2024
(USD MILLION)

TABLE 61 EUROPE: IMMUNOPRECIPITATION MARKET, BY PRODUCT, 2016–2024
(USD MILLION)

TABLE 62 EUROPE: IMMUNOPRECIPITATION REAGENTS MARKET, BY TYPE,
2016–2024 (USD MILLION)

TABLE 63 EUROPE: IMMUNOPRECIPITATION ANTIBODIES MARKET, BY TYPE,
2016–2024 (USD MILLION)

TABLE 64 EUROPE: IMMUNOPRECIPITATION BEADS MARKET, BY TYPE,
2016–2024 (USD MILLION)

TABLE 65 EUROPE: IMMUNOPRECIPITATION MARKET, BY TYPE, 2016–2024 (USD
MILLION)

TABLE 66 EUROPE: IMMUNOPRECIPITATION MARKET, BY END USER, 2016–2024
(USD MILLION)

TABLE 67 ASIA PACIFIC: IMMUNOPRECIPITATION MARKET, BY PRODUCT,
2016–2024 (USD MILLION)

TABLE 68 ASIA PACIFIC: IMMUNOPRECIPITATION REAGENTS MARKET, BY
TYPE, 2016–2024 (USD MILLION)

TABLE 69 ASIA PACIFIC: IMMUNOPRECIPITATION ANTIBODIES MARKET, BY
TYPE, 2016–2024 (USD MILLION)

TABLE 70 ASIA PACIFIC: IMMUNOPRECIPITATION BEADS MARKET, BY TYPE,
2016–2024 (USD MILLION)

TABLE 71 ASIA PACIFIC: IMMUNOPRECIPITATION MARKET, BY TYPE, 2016–2024
(USD MILLION)

TABLE 72 ASIA PACIFIC: IMMUNOPRECIPITATION MARKET, BY END USER,
2016–2024 (USD MILLION)

TABLE 73 ROW: IMMUNOPRECIPITATION MARKET, BY PRODUCT, 2016–2024
(USD MILLION)

TABLE 74 ROW: IMMUNOPRECIPITATION REAGENTS MARKET, BY TYPE,
2016–2024 (USD MILLION)

TABLE 75 ROW: IMMUNOPRECIPITATION ANTIBODIES MARKET, BY TYPE,
2016–2024 (USD MILLION)

TABLE 76 ROW: IMMUNOPRECIPITATION BEADS MARKET, BY TYPE, 2016–2024
(USD MILLION)

TABLE 77 ROW: IMMUNOPRECIPITATION MARKET, BY TYPE, 2016–2024 (USD MILLION)

TABLE 78 ROW: IMMUNOPRECIPITATION MARKET, BY END USER, 2016–2024 (USD MILLION)

TABLE 79 EXPANSIONS, 2016–2018

TABLE 80 COLLABORATIONS, PARTNERSHIPS, AND AGREEMENTS, 2016–2018

TABLE 81 PRODUCT LAUNCHES, 2016–2018

TABLE 82 ACQUISITIONS, 2016-2018

List Of Figures

LIST OF FIGURES

FIGURE 1 IMMUNOPRECIPITATION MARKET

FIGURE 2 RESEARCH DESIGN

FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATIONS, AND REGION

FIGURE 4 BOTTOM-UP APPROACH

FIGURE 5 TOP-DOWN APPROACH

FIGURE 6 DATA TRIANGULATION METHODOLOGY

FIGURE 7 IMMUNOPRECIPITATION MARKET, BY PRODUCT, 2018 VS. 2024 (USD MILLION)

FIGURE 8 IMMUNOPRECIPITATION MARKET, BY TYPE, 2018 VS. 2024 (USD MILLION)

FIGURE 9 IMMUNOPRECIPITATION MARKET, BY END USER, 2018 VS. 2024 (USD MILLION)

FIGURE 10 GEOGRAPHICAL SNAPSHOT OF THE IMMUNOPRECIPITATION MARKET

FIGURE 11 INCREASING NUMBER OF RESEARCH ACTIVITIES IN THE LIFE SCIENCES INDUSTRY IS A KEY DRIVER FOR THE IMMUNOPRECIPITATION MARKET

FIGURE 12 KITS TO CONTINUE TO DOMINATE THE IMMUNOPRECIPITATION MARKET IN 2024

FIGURE 13 INDIVIDUAL IP ACCOUNTED FOR THE LARGEST SHARE OF THE NORTH AMERICAN IMMUNOPRECIPITATION MARKET IN 2018

FIGURE 14 IMMUNOPRECIPITATION MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES

FIGURE 15 LIFE SCIENCES R&D SPENDING, GLOBAL VS. US (USD BILLION)

FIGURE 16 NORTH AMERICA: IMMUNOPRECIPITATION MARKET SNAPSHOT

FIGURE 17 ASIA PACIFIC: IMMUNOPRECIPITATION MARKET SNAPSHOT

FIGURE 18 IMMUNOPRECIPITATION MARKET (GLOBAL) COMPETITIVE LEADERSHIP MAPPING, 2017

FIGURE 19 RANK OF COMPANIES IN THE GLOBAL IMMUNOPRECIPITATION MARKET, 2017

FIGURE 20 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT

FIGURE 21 ABCAM: COMPANY SNAPSHOT

FIGURE 22 GENSCRIPT: COMPANY SNAPSHOT

FIGURE 23 MERCK KGAA: COMPANY SNAPSHOT

FIGURE 24 BIO-RAD LABORATORIES: COMPANY SNAPSHOT
FIGURE 25 TAKARA BIO: COMPANY SNAPSHOT

I would like to order

Product name: Immunoprecipitation Market by Product (Kit, Reagent (Antibodies, Magnetic Buffer)), Type (Individual IP, Coimmunoprecipitation, CHIP), End User (Academics, Research Institutes, Pharmaceutical and Biotechnology Companies) - Global Forecast to 2024

Product link: <https://marketpublishers.com/r/l2B98692BC3EN.html>

Price: US\$ 5,650.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/l2B98692BC3EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970